The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia

A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardi, Maria Rosa, Zingaropoli, Maria Antonella, Pasculli, Patrizia, Perri, Valentina, Tartaglia, Matteo, Valeri, Serena, Russo, Gianluca, Conte, Antonella, Mastroianni, Claudio Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361089/
https://www.ncbi.nlm.nih.gov/pubmed/32688146
http://dx.doi.org/10.1016/j.jneuroim.2020.577323
Descripción
Sumario:A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia (infection). At the infection time point, no differences in the percentages of immune activation and immunesenescence of CD4+ and CD8+ T-cells were observed compared to the pre-infection time point. Our evaluation seems to confirm that teriflunomide controls T-cells immune activation and immunosenescence suggesting that teriflunomide should not be discontinued in MS patients with an active COVID-19 pneumonia.

Ejemplares similares